Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Counterfeiting Task Force Has Standardized Reporting In Its Sights

Executive Summary

FDA's Counterfeit Drug Task Force interim report is expected to propose measures that would standardize how such drugs are reported to the agency

You may also be interested in...



FDA Anti-Counterfeiting Public Meeting To Display Current Technology

FDA's public meeting on drug counterfeiting Oct. 15 will feature vendor displays of current anti-counterfeiting technology

FDA Counterfeiting Task Force To Look At Tighter Wholesaler Licensing

An FDA task force could look to Florida's new drug wholesaler licensing requirements as a model that all states should adopt to combat counterfeiting

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel